Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

385854

registered interest
date	25/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Intensive Care: Hospital Beds
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many intensive care unit beds there are per capita in the UK.
tabling member constituency	Colne Valley
tabling member printed	Jason McCartney
uin	4316
answer	answer is ministerial correction date of answer 03/07/2015 answer text <p>NHS Blood and Transplant launched a new United Kingdom-wide organ donation and transplantation strategy in July 2013. <em>Taking Organ Transplantation to 2020</em> sets out the action necessary to increase organ donation and transplant rates building on the significant increase in donor and transplant rates since 2008. It is vital that all potential donors are identified and referred to the specialist donation team. The strategy recognises that commissioners should keep the demand for intensive care beds under review to ensure that intensive care capacity is not a barrier to donation.</p><p> </p><p> </p><p> </p><p>There were 10.6 adult critical care, paediatric intensive care and neonatal intensive care beds per 100,000 population in England in May 2015. The numbers of such beds in the rest of the United Kingdom is a matter for the devolved administrations.</p><p> </p><p> </p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 4312 question first answered 03/07/2015 11:48:51 answering member 3918 label Biography information for Jane Ellison
tabling member	3953 label Biography information for Jason McCartney

227878

registered interest
date	17/03/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Meningitis: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, pursuant to the Answer of 11 March 2015 to Question 226346, when he expects negotiations with GlaxoSmithKline on the meningitis B vaccine to be concluded.
tabling member constituency	Colne Valley
tabling member printed	Jason McCartney
uin	227877
answer	answer is ministerial correction date of answer 24/03/2015 answer text <p>We are seeking to reach a positive conclusion to the negotiations with GlaxoSmithKline for supply of the meningococcal B (MenB) vaccine, Bexsero<sup>® </sup>at a cost-effective price, as recommended by the Joint Committee on Vaccination and Immunisation, as soon as possible.</p><p> </p><p> </p><p> </p><p>The Department has had a number of meetings with the manufacturer and is continuing to meet.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 227878 question first answered 24/03/2015 17:25:29 answering member 3918 label Biography information for Jane Ellison
tabling member	3953 label Biography information for Jason McCartney

227879

registered interest
date	17/03/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Meningitis: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps he is taking with officials of his Department to expedite negotiations with GlaxoSmithKline on the meningitis B vaccine.
tabling member constituency	Colne Valley
tabling member printed	Jason McCartney
uin	227878
answer	answer is ministerial correction date of answer 24/03/2015 answer text <p>We are seeking to reach a positive conclusion to the negotiations with GlaxoSmithKline for supply of the meningococcal B (MenB) vaccine, Bexsero<sup>® </sup>at a cost-effective price, as recommended by the Joint Committee on Vaccination and Immunisation, as soon as possible.</p><p> </p><p> </p><p> </p><p>The Department has had a number of meetings with the manufacturer and is continuing to meet.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 227877 question first answered 24/03/2015 17:25:29 answering member 3918 label Biography information for Jane Ellison
tabling member	3953 label Biography information for Jason McCartney

170714

registered interest
date	16/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Dialysis Machines
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, pursuant to the Answer of 10 December 2014 to Question 217116, which clinical commissioning groups were consulted about the proposed changes to the commissioning of renal services; and in what form such consultation took place.
tabling member constituency	Colne Valley
tabling member printed	Jason McCartney
uin	218930
answer	answer is ministerial correction date of answer 07/01/2015 answer text <p>Consultation both with clinical commissioning groups (CCGs) and the wider public concerning the transfer of commissioning responsibility of Renal Dialysis from NHS England to CCGs is ongoing.</p><p> </p><p> </p><p> </p><p>The Department has launched a public consultation which closes on 9 January 2015. The consultation considers how to transfer commissioning responsibility and what would need to happen to ensure a smooth transition and maintain both service standards and patient safety. All CCGs are invited to comment on the proposed changes.</p><p> </p><p> </p><p> </p><p>Some clinical commissioners were consulted in their roles as part of the Task and Finish group, as referenced in my previous answer of 10 December, <a href="http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2014-12-03/217116/" target="_blank">217116</a>.</p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 07/01/2015 17:39:42 answering member 3918 label Biography information for Jane Ellison
tabling member	3953 label Biography information for Jason McCartney

167786

registered interest
date	03/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Dialysis Machines
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, pursuant to the Answer of 25 November 2014 to Question 215404, which organisations and individuals were consulted by NHS England when it was developing its proposal to move commissioning of dialysis to clinical commissioning groups; and what the contents were of the submissions received in response to that consultation.
tabling member constituency	Colne Valley
tabling member printed	Jason McCartney
uin	217116
answer	answer is ministerial correction date of answer 10/12/2014 answer text <p>NHS England put its proposals for transferring commissioning responsibility for renal dialysis services and morbid obesity surgery services from NHS England to clinical commissioning groups (CCGs) to the Prescribed Specialised Services Advisory Group in September 2014. These proposals were developed in partnership with the NHS Commissioning Assembly Task and Finish Group on Specialised Service commissioning. The Task and Finish Group is made of clinical commissioners from around the country.</p><p> </p><p> </p><p> </p><p>The Task and Finish group was asked by NHS England to advise on development of proposals for enhancing specialised service commissioning in 2015-16, specifically proposals that would enable improved pathway integrity. NHS England presented the proposed direction of travel for specialised commissioning in 2015-16 to the chairs of Clinical Reference Groups earlier in the year.</p><p> </p><p> </p><p> </p><p>NHS England has advised that they are in dialogue with key stakeholders about both the opportunities and challenges of transferring commissioning responsibility for renal services from NHS England to CCGs.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 10/12/2014 16:49:53 answering member 3918 label Biography information for Jane Ellison
tabling member	3953 label Biography information for Jason McCartney

61335

registered interest
date	11/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many patients have not received homecare medicines and products on time for treatment of (a) cystic fibrosis, (b) HIV and (c) rheumatoid arthritis in the last year.
tabling member constituency	Colne Valley
tabling member printed	Jason McCartney
uin	200204
answer	answer is ministerial correction date of answer 18/06/2014 answer text <p>This information is not collected by the Department or NHS England.</p> answering member constituency North Norfolk answering member printed Norman Lamb question first answered 18/06/2014 15:04:47 answering member 1439 label Biography information for Norman Lamb
tabling member	3953 label Biography information for Jason McCartney

60646

registered interest
date	09/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cystic Fibrosis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps he is taking to ensure that high-cost drugs are delivered to cystic fibrosis patients on time.
tabling member constituency	Colne Valley
tabling member printed	Jason McCartney
uin	199708
answer	answer is ministerial correction date of answer 16/06/2014 answer text <p>It is important that patients, including those with cystic fibrosis, get those high cost drugs provided through homecare services on time.</p><p> </p><p>The Department commissioned a review of homecare medicine supply arrangements to ensure they deliver the best value for patients, the National Health Service and the provider market. The review report, <em>Homecare Medicines: </em><em>Towards a Vision for the Future,</em> was published in December 2011 and is available at:</p><p> </p><p>http://media.dh.gov.uk/network/121/files/2011/12/111201-Homecare-Medicines-Towards-a-Vision-for-the-Future2.pdf</p><p> </p><p>The outcome of subsequent improvement work is summarised in the further report, <em>Homecare Medicines: Towards a Vision for the Future - Taking Forward the Recommendations</em>, published in May 2014 and available at:</p><p> </p><p>www.uhns.nhs.uk/AboutUs/NHSHomecareMedicinesinEngland.aspx</p><p> </p><p>NHS England issued a patient safety alert on minimising the risks of omitted and delayed medicines for patients receiving homecare services on 10 April 2014. This recommended that all healthcare organisations that commission clinical homecare services:</p><p>- establish if medicine homecare services were used by their organisation and if incidents of omitted and delayed medicines had occurred;</p><p>- consider whether immediate action needed to be taken locally and, if required, develop an action plan, to reduce risk and the potential risk to patients;</p><p>- disseminate the alert to all medical, nursing, pharmacy and other staff involved in the care of homecare patients; and</p><p>- report patient safety incidents concerning homecare to the National Reporting and Learning Service.</p><p> </p><p>A copy of the patient safety alert is available at:</p><p> </p><p>www.england.nhs.uk/wp-content/uploads/2014/04/psa-omitted-delayed-meds.pdf</p><p> </p><p>The Department continues to work with NHS England, homecare companies, pharmaceutical suppliers and the NHS to ensure that homecare arrangements are safe and deliver value for the NHS and improved outcomes for patients.</p><p> </p> answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter grouped question UIN 199709 question first answered 16/06/2014 13:15:27 answering member 3932 label Biography information for Dr Dan Poulter
tabling member	3953 label Biography information for Jason McCartney

60647

registered interest
date	09/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Home Care Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what recent assessment he has made of the effectiveness of the commissioning of homecare services by the NHS.
tabling member constituency	Colne Valley
tabling member printed	Jason McCartney
uin	199709
answer	answer is ministerial correction date of answer 16/06/2014 answer text <p>It is important that patients, including those with cystic fibrosis, get those high cost drugs provided through homecare services on time.</p><p> </p><p>The Department commissioned a review of homecare medicine supply arrangements to ensure they deliver the best value for patients, the National Health Service and the provider market. The review report, <em>Homecare Medicines: </em><em>Towards a Vision for the Future,</em> was published in December 2011 and is available at:</p><p> </p><p>http://media.dh.gov.uk/network/121/files/2011/12/111201-Homecare-Medicines-Towards-a-Vision-for-the-Future2.pdf</p><p> </p><p>The outcome of subsequent improvement work is summarised in the further report, <em>Homecare Medicines: Towards a Vision for the Future - Taking Forward the Recommendations</em>, published in May 2014 and available at:</p><p> </p><p>www.uhns.nhs.uk/AboutUs/NHSHomecareMedicinesinEngland.aspx</p><p> </p><p>NHS England issued a patient safety alert on minimising the risks of omitted and delayed medicines for patients receiving homecare services on 10 April 2014. This recommended that all healthcare organisations that commission clinical homecare services:</p><p>- establish if medicine homecare services were used by their organisation and if incidents of omitted and delayed medicines had occurred;</p><p>- consider whether immediate action needed to be taken locally and, if required, develop an action plan, to reduce risk and the potential risk to patients;</p><p>- disseminate the alert to all medical, nursing, pharmacy and other staff involved in the care of homecare patients; and</p><p>- report patient safety incidents concerning homecare to the National Reporting and Learning Service.</p><p> </p><p>A copy of the patient safety alert is available at:</p><p> </p><p>www.england.nhs.uk/wp-content/uploads/2014/04/psa-omitted-delayed-meds.pdf</p><p> </p><p>The Department continues to work with NHS England, homecare companies, pharmaceutical suppliers and the NHS to ensure that homecare arrangements are safe and deliver value for the NHS and improved outcomes for patients.</p><p> </p> answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter grouped question UIN 199708 question first answered 16/06/2014 13:15:27 answering member 3932 label Biography information for Dr Dan Poulter
tabling member	3953 label Biography information for Jason McCartney